<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04280549</url>
  </required_header>
  <id_info>
    <org_study_id>192207</org_study_id>
    <nct_id>NCT04280549</nct_id>
  </id_info>
  <brief_title>Platelet PAR-1 Activation in Health and Diabetes</brief_title>
  <official_title>Platelet PAR-1 Activation in Health and Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Platelet activation has been associated with bad events like heart attack and stroke. There&#xD;
      are a variety of platelet activators that regulate how active a platelet is. We are&#xD;
      interested in Protease-activated receptors (PAR)-1. We are currently studying PAR-1&#xD;
      activation in persons with severe peripheral artery disease. We seek, through this project,&#xD;
      to understand PAR-1 activation in persons without peripheral artery disease. As many patients&#xD;
      with peripheral artery disease have diabetes, we will also evaluate PAR-1 activation in&#xD;
      persons with type 2 diabetes. In addition we will assess the impact of the glucagon-like&#xD;
      peptide (GLP)-1 signaling pathway on platelet activation. Levels of platelet activation will&#xD;
      be determined using platelet aggregation experiments and assessment of platelet-monocyte&#xD;
      aggregates in peripheral blood.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 1, 2018</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Platelet Activation</measure>
    <time_frame>One day</time_frame>
    <description>Number of dilysyl-MDA cross-links formed in human platelets</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Protease Activated Receptor-1 Activation</measure>
    <time_frame>One day</time_frame>
    <description>Number of cleaved PAR-1 receptors in proportion to number of uncleared PAR-1 receptors</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Type 2 Diabetes</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Healthy Subjects</arm_group_label>
    <description>Subjects will have a single visit where a short medical history/list of current medications and single blood draw will be performed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Type 2 Diabetic Subjects</arm_group_label>
    <description>Subjects will have a single visit where a short medical history/list of current medications and single blood draw will be performed.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Type 2 diabetic and healthy subjects&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy men and women ≥60 years of age OR&#xD;
&#xD;
          -  Type 2 diabetic men and women ≥60 years of age&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active cancer&#xD;
&#xD;
          -  Prior myocardial infarction, prior stroke, diagnosed peripheral artery disease&#xD;
&#xD;
          -  Severe liver (cirrhosis, cancer, or end-stage liver disease), kidney disease (eGFR &lt;30&#xD;
             cc/min).&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
&#xD;
          -  Active vasculitis&#xD;
&#xD;
          -  Anticipated lifespan &lt; 2 years&#xD;
&#xD;
          -  Current use of a DOAC&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joshua Beckman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>February 18, 2020</study_first_submitted>
  <study_first_submitted_qc>February 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 21, 2020</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University Medical Center</investigator_affiliation>
    <investigator_full_name>Joshua Beckman</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD that underlie results in a publication, after deidentification (text, tables, figures, and appendices).</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>Beginning 9 months and ending 36 months following article publication.</ipd_time_frame>
    <ipd_access_criteria>Proposals may be submitted up to 36 months following article publication. After 36 months the data will be available in our University's data warehouse but without investigator support other than deposited metadata. (Link to be provided).</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

